-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx Announces Publication Of New Clinical Manuscript Suggesting That Nu.Q H3.1 Biomarker Has Potential To Inform Clinical Care In Critically-Ill ICU Patients In Assessment Of Sepsis, Organ Failure And Subphenotypes

Benzinga·06/12/2025 12:38:22
Listen to the news

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care

HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and subphenotypes.

About the Study

This study aimed to evaluate H3.1 nucleosomes in critical illness, assessing their relationship with sepsis, organ failure, inflammatory subphenotypes and outcomes.

The MARS cohort was used, comprising of consecutive Intensive Care Unit patients (n=1713 patients), with plasma samples collected on days 0, 2 and 4 (n=3671 plasma samples).

H3.1 nucleosome concentrations were measured using the Nu.Q® NETs Immunoassay at baseline and longitudinally.

The relationship between H3.1 nucleosome concentrations and clinical outcomes was investigated.